Project/Area Number |
26460659
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Laboratory medicine
|
Research Institution | Tokyo University of Pharmacy and Life Science |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
木庭 新治 昭和大学, 医学部, 准教授 (20276546)
礒 良崇 昭和大学, 大学共同利用機関等の部局等, 准教授 (60384244)
佐藤 健吾 東京薬科大学, 生命科学部, 助教 (70549930)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 動脈硬化 / 冠動脈疾患 / ペプチド / バイオマーカー / 創薬 / リスクファクター |
Outline of Final Research Achievements |
The present study (cellular, animal, and clinical research) provides the first evidence to demonstrate that new vasoactive peptides regulate atherosclerosis. The atherosclerosis is stimulated by cardiotrophin-1, fetuin-A, kisspeptin-10, and stanniocalcin (STC)-2-derived segments, but is suppressed by STC-1, omentin-1, tumor necrosis factor-stimulated gene-6 (TSG-6), and urocortin-1. This study also shows that plasma levels of kisspeptin-10, omentin-1, and TSG-6 may become candidates for biomarker of coronary atherosclerosis in patients with ischemic heart disease. Further studies are needed to make anti-atherosclerotic drugs on the basis of the good peptides, such as omentin-1, and TSG-6, and urocortin-1.
|